Another approach is enhancing macrophage homing to tumours by upregulating chemokine receptors like CCR2 or CXCR3, which can significantly improve CAR-M migration and retention at tumour sites, thereby boosting therapeutic efficacy. Here, CCR2 is linked to neoplasm.